UK markets closed

DexCom, Inc. (0A4M.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
76.43+1.21 (+1.61%)
At close: 07:14PM BST

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Sector(s)
Industry
Full-time employees6,300

Key executives

NameTitlePayExercisedYear born
Mr. Kevin Ronald SayerExec. Chairman, CEO & Pres2.39MN/A1958
Mr. Jereme M. SylvainExec. VP, CFO & Chief Accounting Officer783.16kN/A1980
Mr. Jacob Steven LeachExec. VP & CTO915.93kN/A1978
Mr. Chad M. PattersonExec. VP of Global Marketing770.49kN/A1982
Mr. Paul R. FlynnExec. VP of Global Revenue761.52kN/A1969
Mr. Barry J. ReganExec. VP of Global OperationsN/AN/A1973
Mr. Shelly Ramasamy SelvarajSr. VP & Chief Information OfficerN/AN/A1959
Mr. Sean ChristensenDirector of Corp. Affairs & Head of Investor RelationsN/AN/AN/A
Mr. Michael BrownExec. VP & Chief Legal OfficerN/AN/A1970
Mr. Matthew DolanSr. VP of Strategy, Corp. Devel. & New MarketsN/AN/A1981
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Corporate governance

DexCom, Inc.’s ISS governance QualityScore as of 1 July 2022 is 8. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.